In patients with advanced chronic obstructive pulmonary disease (COPD), the lung’s vascular network is often severely thinned or damaged. This structural loss makes it unclear whether selective pulmonary vasodilators—treatments designed to expand these vessels—provide any real clinical benefit.
In a recently published study, researchers—including CVC faculty members Drs. Sean van Diepen and Jason Weatherald—investigated whether inhaled nitric oxide (iNO) could improve exercise capacity in patients with mild-to-severe COPD who did not have low blood oxygen (hypoxemia) or high blood pressure in the lungs (pulmonary hypertension). The study also sought to identify whether specific structural or functional factors could serve as predictors of response to the treatment.
This randomized clinical trial enrolled 61 participants from community COPD clinics to evaluate cycling exercise performance while breathing either iNO or a placebo. To evaluate baseline lung and heart health, as well as vascular density, researchers used a combination of pulmonary function testing, echocardiography, and quantitative CT scans.
While iNO did not improve exercise capacity for the average participant, the study found that patients with a higher volume of tiny blood vessels experienced significant improvements. These responders showed increased oxygen uptake, more efficient breathing, and reduced shortness of breath. This suggests that the treatment is most effective in patients who have not yet experienced vascular pruning—the progressive loss of the lung’s smallest blood vessels.
These findings identify a distinct COPD endotype uniquely responsive to selective pulmonary vasodilators. By demonstrating that iNO works specifically in patients with preserved small-vessel volume, this study helps clarify the variable results of past research and establishes pulmonary vascular health as a critical factor in COPD. This signals a need for future research into targeted therapies to reduce shortness of breath and improve exercise tolerance across the disease spectrum.
